EMA gives biosimilar bevacizumab positive opinion
medwireNews: The EMA has given a positive opinion recommending marketing authorization in Europe for use of a biosimilar formulation of the vascular endothelial growth factor (VEGF)-A inhibitor bevacizumab.
The biosimilar bevacizumab (Zirabev; Pfizer Europe MA EEIG, Sandwich, UK) may be given in combination with a platinum-based regimen to treatment-naïve patients with inoperable, advanced, metastatic, or recurrent non-small-cell lung cancer without predominantly squamous cell histology.
In addition, the biosimilar may be used as a first-line treatment given alongside interferon alfa-2a for patients with advanced or metastatic renal cell cancer.
Other indications include treatment in combination with chemotherapy for metastatic colorectal cancer, metastatic breast cancer, and recurrent or metastatic carcinoma of the cervix.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group